Notably, 319 posts (20.9%) expressed specific concerns about GLP-1 medications increasing cancer risk, while 100 posts (6.5%) discussed the potential of GLP-1 agonists to reduce future obesity-related cancer risk. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.